FINANCIAL TEAR SHEET — Q2 2010

Company Overview Non-GAAP Diluted EPS

Gilead Sciences, Inc. (NASDAQ: GILD) is a research-based biopharmaceutical company that Q2 2010 up 22% over Q2 2009
discovers, develops and commercializes innovative medicines in areas of unmet need. With
$1.25
each new discovery and experimental drug candidate, we seek to improve the care of patients $670.6
$1.00 $955.3
suffering from life-threatening diseases worldwide. Gilead’s primary areas of focus include: HIV/ $699
$860.6
AIDS, liver diseases, respiratory diseases, and cardiovascular/metabolic diseases. $0.75 $622.9

$0.50
Our portfolio of over 13 marketed products contributing to our revenue stream through direct
or partner promotion includes Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir $0.25

disoproxil fumarate 300 mg), the first single tablet regimen for HIV Infection; Viread® (tenofovir $0.00
q2 09 q3 09 q4 09 q1 10 q2 10
disoproxil fumarate) for the treatment of both HIV infection and chronic hepatitis B; Letairis®
Note: For the 2009 and 2010 periods, non-GAAP diluted EPS excludes the after-tax impact of
(ambrisentan), a once-daily oral treatment for pulmonary arterial hypertension; Tamiflu®
acquisition, restructuring and stock-based compensation expenses.
On January 1, 2009, Gilead adopted guidance (formerly known as APB 14-1) on a retrospective
basis for its convertible senior notes. GAAP and non-GAAP net income and diluted EPS
(oseltamivir phosphate), the first and only neuraminidase inhibitor tablet for the treatment amounts have been adjusted from that which was previously reported to reflect additional
after-tax interest expense.

and prevention of influenza A and B; Ranexa® (ranolazine), an extended-release tablet for the
treatment of chronic angina; and Lexiscan® (regadenoson) injection, the first A2A adenosine Total Revenues
receptor agonist for use as a pharmacologic stress agent in radionuclide MPI studies. In addition, Q2 2010 up 17% over Q2 2009
Cayston® (aztreonam lysine 75 mg powder and solvent for nebuliser solution) for cystic fibrosis $ In Millions
$2,500
was approved in the U.S., EU, Canada and Australia. $2,032.4 $2,085.9
$1,927.2
$2,000 $1,801.4
Gilead was founded in 1987 in Foster City, California. The company has expanded rapidly over the $1,647.2
$1,500
past two decades, with annual product revenues now exceeding $6.4 billion, operations spanning
three continents (North America, Europe and Australia) with approximately 3,800 employees. $1,000

Second Quarter 2010 Financial Highlights $500

>> Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to
$0
total revenues of $1.65 billion for the second quarter of 2009. q2 09 q3 09 q4 09 q1 10 q2 10

>> Non-GAAP net income for the second quarter of 2010, which excludes after-tax acquisition-
Operating Cash Flows
related expenses, restructuring expenses and stock-based compensation expenses, was
$760.7 million, or $0.85 per diluted share. $ In Millions
$955.3
$1,000
>> Product sales increased 15 percent to $1.81 billion for the second quarter of 2010, compared $860.6

to $1.57 billion in the second quarter of 2009. $750 $670.6 $699

$622.9
>> As of June 30, 2010, Gilead had cash, cash equivalents and marketable securities of $4.22
billion compared to $3.90 billion as of December 31, 2009. $500

>> Gilead generated $1.37 billion of operating cash flow for the first six months of 2010 including
$250
$699.0 million in the second quarter of 2010.
$0
q2 09 q3 09 q4 09 q1 10 q2 10
Note: On January 1, 2009, Gilead adopted guidance (formerly SFAS 160) on a retrospective basis
for its noncontrolling interest. Accordingly, the operating cash flow amounts have been
adjusted from that which was previously reported.

13 Products Contributing to Revenue Stream Core Pipeline Product Candidates

Through Direct Sales or Partner Promotion

Phase Filed New Drug

I II III Application
HIV/AIDS HIV/AIDS
Bristol-Myers Squibb (US and EU) HIV/AIDS
CMV Retinitis/AIDS Japan Tobacco (Japan)
Merck (Developing Countries) TMC 278/Truvada FDR
Elvitegravir (integrase inhibitor)
Integrase FDR “Quad” (elvitegravir/FTC/TDF/cobicistat)
HIV/AIDS
HIV/AIDS Japan Tobacco (Japan) Cobicistat (PK enhancer)
Japan Tobacco (Japan) Chronic Hepatitus B
GSK (Asia) Liver Disease
GS 9190 (polymerase inhibitor) — HCV
1991 1996 1998 2000 2002 2004 2006 2007 2008 2009 GS 9256 (protease inhibitor) — HCV
GS 9450 (caspase inhibitor) — NASH
Respiratory
Ambrisentan (ERA) — IPF
Age-related Aztreonam for Inhalation Solution — CF (B. Cepacia)
Macular Degeneration Pulmonary Arterial
OSI (US) / Pfizer (OUS) Hypertension Aztreonam for Inhalation Solution — Bronchiectasis
Severe Fungal Infections
Astellas (US and Canada) GSK (EU) GS 6201 (A2B adenosine antagonist) — Pulmonary Diseases
Sumitomo (Japan) Cystic Fibrosis Cardiovascular/Metabolic

Chronic Hepatitis B Regadenoson (stress agent) — Myocardial Perfusion Imaging Filed with the EMEA
GSK (Asia, Latin America) Cicletanine (antihypertensive) — PAH
Ranolazine (late sodium current ihibitor) — Diastolic Heart Failure

Influenza A & B GS 9667 (partial A1 adenosine agonist) — Diabetes/Dyslipidemia

Roche (Worldwide) Chronic Angina Myocardial Perfusion Imaging
Menarini (EU) Astellas (US and Canada) Note: E xcludes research and preclinical programs
Senior Leadership First Global Stockbroking Ltd. ThinkEquity
John C. Martin, PhD Kavita Thomas Brian Scorney
Chairman and Chief Executive Officer ISI Group Wedbush Pac Grow Life Sciences
John F. Milligan, PhD Mark Schoenebaum Y. Katherine Xu, PhD
President and Chief Operating Officer Jefferies & Company William Blair & Company
Norbert W. Bischofberger, PhD Thomas Wei John Sonnier
Executive Vice President, Research and JPMorgan
Development and Chief Scientific Officer Geoffrey Meacham, PhD *Last updated 7/20/2010 .
Gregg H. Alton Lazard Capital Markets
Executive Vice President, Corporate and Medical Joel Sendek
Affairs
Leerink Swann
Kevin Young Joshua Schimmer, MD
Executive Vice President, Commercial
Morgan Joseph
Operations
Shiv Kapoor
Kristen M. Metza
Morningstar
Senior Vice President, Human Resources
Karen Andersen
Robin L. Washington
Needham
Senior Vice President and Chief Financial Officer
Alan Carr
Analyst Coverage Oppenheimer
Argus Research Company Bret Holley, PhD
John Eade Piper
Bank of America Merrill Lynch M. Ian Somaiya
Rachel McMinn RBC Capital Markets
Barclays Capital Jason Kantor
Jim Birchenough, MD Robert W. Baird & Company
BMO Capital Markets Thomas J. Russo, CFA
Jason Zhang, PhD Roth Capital Markets
BWS Financial Jason Kantor
Hamed Khorsand Sanford C. Bernstein & Company
Citigroup Geoffrey Porges, PhD
Yaron Werber, MD Standard and Poors
Cowen & Company Steven Silver
Phil Nadeau, PhD Summer Street Research Partners
Carol Werther

Stock Chart Contact information

300
>> NASDAQ: GILD Gilead Sciences, Inc.
>> 52-Week Range: Investor Relations
250
$31.83–$50.00* 333 Lakeside Drive
>> Market Cap: Foster City, CA 94404
200 29.37 billion* Phone: 1-800-445-3235
Fax: 650-522-5853
150 *As of 7/20/2010. Email: investor_relations@gilead.com
www.gilead.com
100

50 Gilead Sciences
NBI Index
0
S&P500 Index
05

05

05

06

0
01

01
00

00

00

00

00
00

00
00

00

00

00

00

00

00

00
20

20

20

20

/2

/2
/2

/2

/2

/2

/2
/2

/2
/2

/2

/2

/2

/2

/2

/2

/2
0/

0/

0/

9/

31

30
/31
29

31
31

30

31

/31

/31
28
30

30

30

30

30

30
3

/3

/2

3/

6/
3/
3/

3/
6/
3/

9/
6/

9/

6/

9/

6/

9/

6/

9/
12

12

12
12

12